Table 1. Summary of HIV clinical studies using T cells.
| Strategy | Patients | Status | Clinical Trial ID |
|---|---|---|---|
| CD4 zeta-CAR T cell |
ART experienced | 11+ year persistence tissue-specific efficacy in vivo |
NCT01013415[30] |
| Artificial high- affinity gag- specific TCR |
Responsive to ART treatment, HLA-A2+ |
Active and recruiting | NCT00991224 |
| Expanded autologous CD8 T cells |
CD4 between 100-400 cells/mm3 |
No adverse events, no statistically significant efficacy |
NCT00000756[3] |
| Expanded autologous CD8 T cells |
CD4 above 200 cells/mm3 |
Moderate persistence, homing to reservoir sites |
NCT00110578[35] |
| CCR5 deleted CD4 T cells |
ART experienced, responsive and un- responsive to treatment |
Active and recruiting |
NCT01044654, NCT00842634 |
| CCR5 deleted CD4 T cells |
HIV+ with CD4>500 cells/ mm3 and viral load between 1,000 and 1,000,000 copies/mL |
Active and not recruiting | NCT01252641 |